The constant noise of a ventilator, monitor alarms, and infusion pumps predispose the patient to:

Choice A rationale

The normal range for serum creatinine is approximately 0.6 to 1.2 mg/dL for adults. A value of 2.1 mg/dL is significantly elevated, indicating a reduction in the glomerular filtration rate and impaired renal function. In the context of a myocardial infarction, low cardiac output can lead to pre-renal azotemia or acute tubular necrosis. This elevation serves as a primary marker for the development of acute kidney injury, reflecting the kidneys' inability to clear metabolic waste effectively.

Choice B rationale

Serum osmolality represents the concentration of particles dissolved in the blood, with a normal range typically between 275 and 295 mOsm/kg H2O. A value of 290 mOsm/kg H2O is within the normal physiological limits. This indicates a stable balance of electrolytes and water in the plasma. Since the value is normal, it does not suggest an increased risk or current state of acute kidney injury or fluid volume disturbances that would damage renal tissue.

Choice C rationale

The normal range for serum magnesium is approximately 1.3 to 2.1 mEq/L. A magnesium level of 2.0 mEq/L is within the normal therapeutic range. While electrolyte imbalances can occur during renal failure, a normal magnesium level does not indicate an increased risk of acute kidney injury. Magnesium is primarily excreted by the kidneys, so while its level might rise if injury occurs, the current value of 2.0 mEq/L indicates that renal clearance is currently sufficient.

Choice D rationale

The normal range for blood urea nitrogen (BUN) is typically 10 to 20 mg/dL. A BUN of 20 mg/dL is at the upper limit of the normal range but is not considered an elevated finding that signifies acute kidney injury on its own. BUN can be influenced by protein intake, hydration status, and liver function. Without an accompanying elevation in creatinine, this normal BUN level does not suggest that the patient is at high risk for kidney failure.

Choice A rationale

While aspirin does possess analgesic properties by inhibiting the synthesis of prostaglandins in the central and peripheral nervous systems, this is not the primary reason for its prescription following a myocardial infarction. In the context of post-MI care, the dose of 325 mg is intended for its systemic vascular benefits rather than simple pain relief. Other medications or lower doses of aspirin might be used for pain, but the clinical priority here is cardiovascular protection.

Choice B rationale

Aspirin exhibits anti-inflammatory effects by blocking cyclooxygenase enzymes, which reduces the production of mediators that cause tissue swelling and pain. Although inflammation plays a significant role in the progression of atherosclerosis, the specific indication for a client with a history of myocardial infarction focuses more on the immediate prevention of acute thrombotic events. While the anti-inflammatory benefit is present, it is secondary to the critical need for maintaining patency in the coronary arteries.

Choice C rationale

The antipyretic action of aspirin involves acting on the hypothalamus to override an interleukin-induced increase in body temperature. While effective for reducing fever, this pharmacological action is irrelevant to the long-term management of a client with a history of myocardial infarction. Clients in this category are not typically suffering from chronic febrile conditions; therefore, using aspirin for its heat-reducing properties would not provide the specific secondary prevention required for their underlying cardiac pathology.

Choice D rationale

In post-myocardial infarction management, aspirin is primarily used for its antiplatelet aggregate effect. It irreversibly inhibits the cyclooxygenase-1 enzyme within platelets, preventing the formation of thromboxane A2, which is a potent inducer of platelet aggregation. By reducing the ability of platelets to clump together, aspirin decreases the risk of re-occlusion of coronary arteries and prevents subsequent ischemic events. This is the therapeutic cornerstone for long-term survival and reduction of recurrent cardiac mortality.